Study Comparing Chemotherapy and Atezolizumab with or without Bevacizumab for Advanced Liver Cancer

Program Overview

This study is testing two different treatment combinations for advanced liver cancer that cannot be removed by surgery. One group will receive chemotherapy drugs (gemcitabine and cisplatin) along with the immunotherapy drug atezolizumab. The other group will receive the same chemotherapy and immunotherapy drugs, plus an additional drug called bevacizumab. Atezolizumab helps the immune system attack cancer cells, while bevacizumab works by stopping the growth of blood vessels that supply the tumor, potentially slowing its growth. The study aims to find out if the addition of bevacizumab can help control the cancer better than the standard treatment.

Description

The main goal of this study is to see if adding bevacizumab to a combination of chemotherapy and immunotherapy can help patients with advanced liver cancer live longer without the disease getting worse. The study will also look at how well the cancer responds to the treatment and how long patients live overall.

Participants will be randomly assigned to one of two groups:

• Group A: Will receive atezolizumab and bevacizumab along with chemotherapy drugs gemcitabine and cisplatin. These medications will be given through an IV on specific days in a 21-day cycle, which will repeat as long as the treatment is effective and side effects are manageable.

• Group B: Will receive atezolizumab with the same chemotherapy drugs, gemcitabine and cisplatin, but without bevacizumab. This group will also follow a 21-day cycle.

Throughout the study, participants will have regular scans (CT or MRI) and blood tests to monitor their health and the cancer's response to treatment. After completing the study treatment, participants will be followed up for three years to track their progress.

Eligibility Criteria

Locations